Roivant Sciences Officer Eric Venker Files Form 144 to Sell $7.26M in Common Shares

Executive Summary

On November 3, 2026, Eric Venker, an Officer of Roivant Sciences Ltd. (NASDAQ: ROIV), filed a Form 144 notice disclosing the proposed sale of 200,000 common shares with an aggregate market value of approximately $7,262,568.00. The proposed sale is executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2026.

Transaction Details

• Security: Common Shares
• Volume: 200,000 shares
• Aggregate Market Value: $7,262,568.00 (implied price of ~$36.31 per share)
• Broker: Rockefeller Financial LLC
• Source of Shares: Acquired via option exercises and RSU vesting between April 2023 and September 2025.

Prior Sales (Past 3 Months)

The filer has maintained an active selling pace under the 10b5-1 plan, having sold:

• 10/28/2026: 200,000 shares ($7,317,764.00)
• 10/20/2026: 200,000 shares ($7,023,153.39)
• 09/30/2026: 200,000 shares ($7,323,556.00)
• 08/28/2026: 200,000 shares ($7,147,087.91)
• 08/20/2026: 13,909 shares ($512,407.56)

Significance & Market Impact

While the total dollar volume of this sale is substantial ($7.26M), the sale represents less than 0.03% of Roivant's 722.3M outstanding shares and is part of a routine, scheduled Rule 10b5-1 disposition program initiated in mid-2026. Consequently, market impact is rated as Medium, reflecting substantial dollar liquidity but minimal discretionary signaling.